|
Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase. |
|
|
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Celgene; LEO Pharma; Merck Sharp & Dohme; Novartis |
Consulting or Advisory Role - Celgene; Janssen; Merck Sharp & Dohme; Novartis; Roche |
Travel, Accommodations, Expenses - Abbvie; Janssen; Merck Sharp & Dohme; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck Sharp & Dohme; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme |
Research Funding - Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |